Ambenet GmbH Das Ambulante Behandlungsnetz

Leipzig 24 trials 6 recruiting

24 Registered trials

6 Currently recruiting

Organisation

Ambenet GmbH Das Ambulante Behandlungsnetz

Location

Leipzig, Germany

Identifier

ORG-100042545

Address

Wilhelm-Leuschner-Platz 12, Zentrum-Süd, 04107, Germany

Departments

-
--
3004:AmBeNet GmbH
AmBeNet GmbH
General Physician
internal medicine
N/A
NA
Praxis Dr. Stahl
Studienzentrum

Clinical trials at this site (24)

Search interface

A prospective, multi-centre, randomised, double-blind, placebo-controlled Phase III trial to investigate the efficacy and safety of lozenges… Not authorised

2025-521764-35-00 acute pharyngitis 5
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Recruiting

2025-523486-17-00 Obesity 5 2026-06-16
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes ( ENLIGHTEN-1). Recruiting

2025-523657-34-00 Obesity 5 2026-04-13
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee ( ATTAIN-OA PAIN ) Recruiting

2025-522631-34-00 Osteoarthritis 5 2026-01-14
Silexan® in mild to moderate major depressive disorder Recruiting

2025-521744-37-00 Mild to moderate major depressive disorder 5 2025-11-17
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with li… Recruiting

2024-512104-19-00 Irritable Bowel Syndrome 6 2019-11-19
Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Ended

2025-523974-18-00 Obesity 5 2026-04-30
J2A-MC-GZPO: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes J2… Ended

2025-521098-14-00 GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes 5 2025-08-15
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARIT… Ended

2024-515523-11-00 Chronic Weight Management 5 2025-06-09
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA… Ended

2024-515524-36-00 Chronic Weight Management 5 2025-05-30
A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended

2024-512946-41-00 Menstrual Migraine 5 2025-03-05
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5) Ended

2024-511450-49-00 Obesity 5 2024-10-22
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 5 2023-02-28
A research study to see how well CagriSema helps people with excess body weight lose weight Ended

2023-506929-11-00 Overweight and obesity 5 2022-10-17
A prospective, randomised, multi-centre, double-blind, placebo-controlled Phase III trial to investigate the efficacy and safety of lozenges… Halted

2025-521764-35-01 acute pharyngitis 5 2026-01-27
A research study to see how well different doses of CagriSema help people with excess body weight lose weight Ended

2023-509273-24-00 Obesity 5 2024-09-05
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17
A research study to see how well CagriSema helps people with type 2 diabetes and excess body weight lose weight Ended

2023-506931-13-00 Overweight and obesity and type 2 diabetes 5 2023-01-30
Evaluating the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age Ended

2023-508820-37-00 Cytomegalovirus Infection (CMV) 5 2022-02-03
Study of efficacy, safety and tolerability of DFV890 in patients with knee osteoarthritis Ended

2023-507559-30-00 Knee Osteoarthritis 4 2021-11-09
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended

2023-507096-21-00 Chronic or Episodic Migraine (Migraine without aura, mi 5 2021-08-16
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5) Ended

2022-501106-35-00 Obesity Overweight 5